Biosimilar Antibodies & Proteins
In this product category, you will find reports and other services providing you with the most uptodate business and competitive intelligence information on biosimilar antibodies and proteins. The range of products covers industry data as well as in-depth strategic assessment and analysis of biosimilar antibody and protein companies, R&D pipeline, and sales and market information.
Subscribe to
our newsletters!
Showing all 18 results
- 2024 Sales of Therapeutic Antibodies, Proteins, Biosimilars, Gene & Cell Therapy and Therapeutic RNA€ 130.00
- This product provides basic information on drugs on the market and drug candidates in R&D as biosimilar antibodies of Actemra/RoActemra (tocilizumab).€ 200.00
- This product provides basic information on drug candidates in research and development as biosimilar antibodies of Keytruda (pembrolizumab)€ 200.00
- This product provides basic information on approved and investigational antibodies, cell therapies and small molecules targeting CD38.€ 300.00
- 2023 sales data of originator therapeutic proteins and antibodies, selected biosimilars and other biologic drug modalities (gene & cell therapy, RNA)€ 130.00
- Online database of annual global sales of innovator & bioimilar biologics since the year 2007€ 250.00
- This product provides basic information on approved drugs and drug candidates in R&D as biosimilar antibodies of Prolia & Xgeva (denosumab).€ 300.00
- This report provides a competitor evaluation in the field of antibodies, proteins, peptides, RNA and small molecules acting as inibitors of complement C5 or antagonists of the C5a receptor€ 400.00
- This product provides basic information on approved drugs and drug candidates in R&D as biosimilar antibodies of Humira (adalimumab).€ 400.00
- This product provides basic information on approved drugs and drug candidates in R&D as biosimilar or biosuperior antibodies of Soliris (eculizumab).€ 300.00
- This product provides basic information on approved drugs and drug candidates in R&D as biosimilar or biosuperior antibodies of Xolair (omalizumab).€ 300.00
- This product provides basic information on approved drugs and drug candidates in R&D as biosimilar antibodies of Lucentis (ranibizumab)€ 300.00
- This product provides basic information on drug candidates in R&D as biosimilar antibodies of Eylea (aflibercept)€ 300.00
- This product provides basic information on approved drugs and drug candidates in R&D as biosimilar antibodies of Stelara (ustekinumab).€ 300.00
- Sales data of originator therapeutic proteins and antibodies & selected biosimilar antibodies and proteins and other biologics in 2022€ 120.00
- Antibody Target, Technology & Pipeline Database€ 1600.00
- This report provides a compilation of the sales data of originator recombinant therapeutic proteins and antibodies in the calendar year 2021€ 100.00
- Competitive intelligence report about next wave biosimilar antibodies of Lucentis, Eylea, Xolair, Prolia, Stelara, Soliris and More as of December 2019€ 600.00